^
    Back
    Association details:
    Biomarker:CD69 overexpression
    Cancer:Melanoma
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Immunol
    Title:

    CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

    Published date:
    08/15/2022
    Excerpt:
    Further analysis showed that in lung cancer responders, CD69 was upregulated while SBK1 was downregulated and that in melanoma responders, both were upregulated….CD69 and SBK1 are potential predictors of response to cancer immunotherapy using PD-1/PD-L1 blockade.
    DOI:
    10.3389/fimmu.2022.952059